InnoCare Secures China Breakthrough Therapy Status for Marginal Zone Lymphoma Therapy
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
China NMPA
Advertisement
Nuvectis Pharma Announces China Approval of Ciprocopan for PNH
FORT LEE, N.J., July 23, 2026 Nuvectis Pharma, Inc. announced that ciprocopan (NXP100) has received marketing approval from China’s...
Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...
HUTCHMED’s Savolitinib NDA Gains Priority Review in China
Hong Kong / Shanghai | December 30, 2025 — HUTCHMED announced that China’s drug regulator has accepted the New...
Advertisement
